BCL2 and prostate carcinoma: This melatonin-induced inhibition was exemplified following a 48-hour LNCaP co-culture with hrTNF-α and melatonin, which demonstrated that melatonin promoted prostate cancer cell apoptosis through reduction of Bcl-2 as well as Survivin levels, two important carcinogenic survival factors.